# Belizatinib

Cat. No.:	HY-17603				
CAS No.:	1357920-84-3				
Molecular Formula:	C <sub>33</sub> H <sub>44</sub> FN <sub>5</sub> O <sub>3</sub>				
Molecular Weight:	577.73				
Target:	Anaplastic lymphoma kinase (ALK); Trk Receptor				
Pathway:	Protein Tyrosine Kinase/RTK; Neuronal Signaling				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		

®

MedChemExpress

## SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solution:	1 mM	1.7309 mL	8.6546 mL	17.3091 mL
	5 mM	0.3462 mL	1.7309 mL	3.4618 mL
	10 mM	0.1731 mL	0.8655 mL	1.7309 mL

BIOLOGICAL ACTIVITY				
Description	Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC <sub>50</sub> of 0.7 nM for wild-type recombinant ALK kinase.			
IC <sub>50</sub> & Target	IC50: 0.7 nM (ALK) <sup>[1]</sup>			
In Vitro	TSR-011 has antitumour activity in the clinical trials. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## CUSTOMER VALIDATION

• J Pharm Biomed Anal. 2019 Apr 6;171:132-147.

See more customer validations on www.MedChemExpress.com

### REFERENCES

[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA